



US007439393B2

(12) United States Patent
Box et al.**(10) Patent No.: US 7,439,393 B2**
(45) Date of Patent: *Oct. 21, 2008**(54) PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES****(75) Inventors:** Philip Charles Box, Stevenage (GB);
Diane Mary Coe, Stevenage (GB);
Brian Edgar Looker, Stevenage (GB);
Inderjit Singh Mann, Stevenage (GB);
Panayiotis Alexandrou Procopiou,
Stevenage (GB)**(73) Assignee:** Glaxo Group Limited, Greenford,
Middlesex (GB)**(*) Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-
claimer.**(21) Appl. No.: 11/566,346****(22) Filed: Dec. 4, 2006****(65) Prior Publication Data**

US 2008/0003290 A1 Jan. 3, 2008

Related U.S. Application Data**(63)** Continuation of application No. 10/489,569, filed as
application No. PCT/GB02/04140 on Sep. 11, 2002,
now Pat. No. 7,361,787.**(30) Foreign Application Priority Data**Sep. 14, 2001 (GB) 0122201.7
Nov. 9, 2001 (GB) 0126997.6**(51) Int. Cl.****C07C 273/00** (2006.01)**C07C 303/00** (2006.01)**C07C 233/00** (2006.01)**A61K 31/00** (2006.01)**(52) U.S. Cl.** **564/38**; 564/86; 564/194;
514/538; 514/553; 514/567; 514/591; 514/602;
514/630**(58) Field of Classification Search** None
See application file for complete search history.**(56) References Cited****U.S. PATENT DOCUMENTS**2,140,800 A 12/1938 Leemans
3,994,974 A 11/1976 Murakami et al.
4,730,008 A 3/1988 Skidmore et al.
4,853,381 A 8/1989 Finch et al.
4,853,382 A 8/1989 Skidmore et al.
4,908,386 A 3/1990 Finch et al.
4,937,268 A 6/1990 Skidmore et al.
4,963,564 A 10/1990 Skidmore et al.
4,990,505 A 2/1991 Skidmore et al.
4,992,474 A 2/1991 Skidmore et al.
4,997,986 A 3/1991 Mitchell et al.
5,066,678 A 11/1991 Skidmore et al.
5,091,422 A 2/1992 Skidmore et al.
5,099,068 A 3/1992 Mitchell et al.5,109,023 A 4/1992 Mitchell et al.
5,126,375 A 6/1992 Skidmore et al.
5,225,445 A 7/1993 Skidmore et al.
5,243,076 A 9/1993 Skidmore et al.
5,283,262 A 2/1994 Mitchell et al.
5,290,815 A 3/1994 Johnson et al.
5,393,774 A 2/1995 Pieper et al.
5,552,438 A 9/1996 Christensen, IV
5,998,428 A 12/1999 Barnette et al.
7,135,600 B2 11/2006 Biggadike et al.**FOREIGN PATENT DOCUMENTS**DE 3513885 10/1985
DE 3524990 1/1986
DE 4028398 3/1992
EP 0069715 1/1983
EP 69715 1/1983
EP 162576 11/1985
EP 220054 4/1987
EP 220878 5/1987
EP 223410 5/1987
EP 0286242 10/1988
EP 286242 10/1988
EP 303465 2/1989
EP 0317206 5/1989
EP 0416951 1/1991
EP 223671 11/1991
EP 0401966 1/1994
EP 0947498 10/1999
GB 2064336 6/1981
GB 2129691 5/1984
GB 2140800 12/1984

(Continued)

OTHER PUBLICATIONSFuji et al., "Novel phosphodiesterase 4 inhibitor T-440 reverses and
prevents human bronchial contraction induced by allergen," *J*
Pharmacol Exp Ther 284(1):162 (1998).
Landells et al., "Oral administration of the phosphodiesterase
(PDE)4 inhibitor. V11294A inhibits ex-vivo agonist-induced-cell
activation," *Eur Resp J (Jumnu Cong Eur Resp Soc. Geneva)*
12(Suppl. 28) Abst P2393 (Sep. 1998).
McHale et al., "Expression of human recombinant cAMP
phosphodiesterase isozyme IV reverses growth arrest phenotypes in
phosphodiesterase-deficient yeast," *Mol Pharmacol* 39:109-113
(1991).
Nicholson et al., "Differential modulation of tissue function and
therapeutic potential of selective inhibitors of cyclic nucleotide
phosphodiesterase isoenzymes," *Trends Pharmacol Sci* 12:19-27
(1991).

(Continued)

Primary Examiner—Sikarl A Witherspoon
(74) Attorney, Agent, or Firm—Robert J. Smith**(57) ABSTRACT**The invention relates to 4-{(1R)-2-[(6-{2-[(2,6-dichloroben-
zyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hy-
droxymethyl)phenol; and salts and solvates thereof, includ-
ing those which are pharmaceutically acceptable, along with
formulations thereof, combinations thereof, and methods for
the treatment or prophylaxis of mammals by administering
such compounds.**22 Claims, 2 Drawing Sheets**